A record year across all financial and operational metrics On track to deliver future growth targets Initiating annual dividend policy
hVIVO PLC (AIM:HVO) Notice of Results
hVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it
hVIVO PLC (AIM:HVO) Holding(s) in Company – JPMorgan Asset Management (UK) Limited
JP Morgan issued a new TR1 this morning bringing their shareholding to 6.9%, this is of course very positive news that such a large fund is heavily invested in hVIVO
hVIVO PLC (AIM:HVO) Proposed Secondary Placing of Ordinary Shares
Proposed Secondary Placing of not less than 14 million Existing Ordinary Shares in the Company
hVIVO PLC (AIM:HVO) Excellent forward visibility with £80m weighted order book
hVIVO’s Trading Update for 2023 showcases a record-breaking year for the company in all aspects of financial and operational performance.
Analysts Predict hVIVO to Secure Multiple Contracts in 2024 Following Initial Success
Analysts are optimistic about hVIVO PLC (AIM:HVO), a company specializing in scientific trials, following its recent success in securing a £6.3 million contract for common cold treatment research.
hVivo, a drug-testing company saw its share price double from 10p to 22p over the year.
This transformation began earlier this year. hVivo, a drug-testing company saw its share price double from 10p to 22p over the year.
Analyst Predicts Increased Growth for hVIVO After Securing Major RSV Contract
Cavendish analysts believe the market will respond positively to hVIVO PLC’s announcement of a significant respiratory syncytial virus (RSV) drug contract, even though the company’s shares have already surged by
hVIVO PLC (AIM:HVO) £16.8m RSV contract & Trading ahead of guidance
£16.8m full-service RSV contract with top five global pharma client Trading ahead of guidance
US investment bank states that hVIVO is reinforced by powerful industry momentum.
Stifel’s Insight on hVIVO PLC
hVIVO PLC (AIM:HVO) Positive results from flu human challenge study
Positive results from influenza human challenge study conducted by hVIVO Pneumagen to advance antiviral candidate into further clinical studies
hVIVO PLC (AIM:HVO) Interim results
Strong first-half performance and record forward visibility Upgrade of Full Year Revenue and EBITDA Guidance